Ginkgo Bioworks reported Q2 2024 revenue of $56.2 million, down from $80.6 million in Q2 2023. Cell Engineering revenue was $36.2 million while Biosecurity revenue contributed $20.0 million. The company recorded a net loss of $217.2 million compared to $173.3 million in the prior year period, including a $47.9 million goodwill impairment charge and $17.1 million in restructuring costs.The company announced a restructuring plan targeting at least 35% workforce reduction and facilities consolidation, expected to result in $18-22 million in one-time costs. The plan aims to lower operational expenditures while maintaining strategic investments in Foundry, Codebase and AI capabilities. During Q2, Ginkgo launched 10 new cell programs, bringing total active programs to 140, up from 105 in Q2 2023.As of June 30, 2024, Ginkgo maintained $730.4 million in cash and cash equivalents. The company continues to expand its cell programming platform capabilities while shifting its Biosecurity business focus to developing scalable infrastructure and delivering global surveillance programs. Management believes current cash reserves will fund operations for at least 12 months, as it implements cost reduction initiatives while pursuing strategic growth opportunities.

Ginkgo Bioworks reported Q2 2024 revenue of $56.2 million, down from $80.6 million in Q2 2023. Cell Engineering revenue was $36.2 million while Biosecurity revenue contributed $20.0 million. The company recorded a net loss of $217.2 million compared to $173.3 million in the prior year period, including a $47.9 million goodwill impairment charge and $17.1 million in restructuring costs.The company announced a restructuring plan targeting at least 35% workforce reduction and facilities consolidation, expected to result in $18-22 million in one-time costs. The plan aims to lower operational expenditures while maintaining strategic investments in Foundry, Codebase and AI capabilities. During Q2, Ginkgo launched 10 new cell programs, bringing total active programs to 140, up from 105 in Q2 2023.As of June 30, 2024, Ginkgo maintained $730.4 million in cash and cash equivalents. The company continues to expand its cell programming platform capabilities while shifting its Biosecurity business focus to developing scalable infrastructure and delivering global surveillance programs. Management believes current cash reserves will fund operations for at least 12 months, as it implements cost reduction initiatives while pursuing strategic growth opportunities.